Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Klaus Pors

Showing results (11-20 of 54) with videos related to

Pageof 6
Sort By:
Clinical Proteomics|November 1, 2025
Comprehensive proteome profiling of cytochrome P450 isoforms in cancer modelsSadr Ul Shaheed, Ahood A Al-Eidan, Klaus Pors, et al.
Journal of Cellular and Molecular Medicine|July 16, 2022
In vitro radiosensitization of breast cancer with hypoxia-activated prodrugsRadhika Aiyappa-Maudsley, Lina Elsalem, Ali I M Ibrahim, et al.
Biomedicines|April 3, 2021
Intratumoural Cytochrome P450 Expression in Breast Cancer: Impact on Standard of Care Treatment and New Efforts to Develop Tumour-Selective TherapiesSmarakan Sneha, Simon C Baker, Andrew Green, et al.
Bioorganic & Medicinal Chemistry Letters|January 25, 2005
Truncated azinomycin analogues intercalate into DNAMaxwell A Casely-Hayford, Klaus Pors, Laurence H Patterson, et al.
Cancer Immunology, Immunotherapy : CII|August 26, 2017
Therapeutic antibodies against cancer stem cells: a promising approachSmarakan Sneha, Rohit Pravin Nagare, Syama Krishna Priya, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals|October 5, 2021
Cytochrome P450 Binding and Bioactivation of Tumor-Targeted Duocarmycin AgentsAaron G Bart, Goreti Morais, Venu R Vangala, et al.
Journal of Pharmacological and Toxicological Methods|May 17, 2011
Use of the hollow fiber assay for the evaluation of DNA damaging agentsJ Pedro Veiga, Patricia A Cooper, Klaus Pors, et al.
Drug Discovery Today|July 30, 2009
The changing landscape of cancer drug discovery: a challenge to the medicinal chemist of tomorrowKlaus Pors, Frederick W Goldberg, Christopher P Leamon, et al.
Organic & Biomolecular Chemistry|September 21, 2005
Design and synthesis of a DNA-crosslinking azinomycin analogueMaxwell A Casely-Hayford, Klaus Pors, Colin H James, et al.
Biomedicines|December 9, 2020
Aldehyde Dehydrogenases and Prostate Cancer: Shedding Light on Isoform Distribution to Reveal Druggable TargetLuca Quattrini, Maria Sadiq, Giovanni Petrarolo, et al.
Pageof 6

Showing results (11-20 of 54) with videos related to

Sort By:
Pageof 6
Clinical Proteomics|November 1, 2025
Comprehensive proteome profiling of cytochrome P450 isoforms in cancer modelsSadr Ul Shaheed, Ahood A Al-Eidan, Klaus Pors, et al.
Journal of Cellular and Molecular Medicine|July 16, 2022
In vitro radiosensitization of breast cancer with hypoxia-activated prodrugsRadhika Aiyappa-Maudsley, Lina Elsalem, Ali I M Ibrahim, et al.
Biomedicines|April 3, 2021
Intratumoural Cytochrome P450 Expression in Breast Cancer: Impact on Standard of Care Treatment and New Efforts to Develop Tumour-Selective TherapiesSmarakan Sneha, Simon C Baker, Andrew Green, et al.
Bioorganic & Medicinal Chemistry Letters|January 25, 2005
Truncated azinomycin analogues intercalate into DNAMaxwell A Casely-Hayford, Klaus Pors, Laurence H Patterson, et al.
Cancer Immunology, Immunotherapy : CII|August 26, 2017
Therapeutic antibodies against cancer stem cells: a promising approachSmarakan Sneha, Rohit Pravin Nagare, Syama Krishna Priya, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals|October 5, 2021
Cytochrome P450 Binding and Bioactivation of Tumor-Targeted Duocarmycin AgentsAaron G Bart, Goreti Morais, Venu R Vangala, et al.
Journal of Pharmacological and Toxicological Methods|May 17, 2011
Use of the hollow fiber assay for the evaluation of DNA damaging agentsJ Pedro Veiga, Patricia A Cooper, Klaus Pors, et al.
Drug Discovery Today|July 30, 2009
The changing landscape of cancer drug discovery: a challenge to the medicinal chemist of tomorrowKlaus Pors, Frederick W Goldberg, Christopher P Leamon, et al.
Organic & Biomolecular Chemistry|September 21, 2005
Design and synthesis of a DNA-crosslinking azinomycin analogueMaxwell A Casely-Hayford, Klaus Pors, Colin H James, et al.
Biomedicines|December 9, 2020
Aldehyde Dehydrogenases and Prostate Cancer: Shedding Light on Isoform Distribution to Reveal Druggable TargetLuca Quattrini, Maria Sadiq, Giovanni Petrarolo, et al.
Pageof 6